SCOPUS 정보 검색 플랫폼

Volumn 28, Issue 28, 2010, Pages

Trastuzumab treatment in T1ab, node-negative, human epidermal growth factor receptor 2-overexpressing breast carcinomas

(12) Rodrigues, Manuel Jorge a Wassermann, Johanna b Albiges, Laurence c Brain, Etienne b Delaloge, Suzette c Stevens, Denise b Guinebretière, Jean Marc b Mathieu, Marie Christine c Kirova, Youlia a Guillot, Eugénie a Vincent Salomon, Anne a Cottu, Paul H a

a INSTITUT CURIE (France)

b CENTRE RENÉ HUGUENIN (France)

c INSTITUT GUSTAVE ROUSSY (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB; MONOCLONAL ANTIBODY;

ADJUVANT THERAPY; BONE METASTASIS; BRAIN METASTASIS; BREAST CARCINOMA; BREAST SURGERY; CANCER GRADING; CANCER INVASION; CANCER RISK; CANCER SIZE; CANCER SURVIVAL; CLINICAL DECISION MAKING; DRUG EFFICACY; GENE OVEREXPRESSION; HORMONAL THERAPY; HUMAN; LETTER; LUNG METASTASIS; MEDICAL RECORD REVIEW; MEDICAL SOCIETY; MITOSIS INDEX; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE FREE SURVIVAL; SENTINEL LYMPH NODE BIOPSY; ADJUVANT CHEMOTHERAPY; ADULT; AGED; BREAST TUMOR; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; FRANCE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; FRANCE; HUMANS; MIDDLE AGED; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 78049427459 PISSN: 0732183X EISSN: 15277755 Source Type: Journal
DOI: 10.1200/JCO.2010.29.7952 Document Type: Letter

Times cited : (34)

References (13)

1
- 0032535095
- Medical audit after 26,711 breast imaging studies: Improved rate of detection of small breast carcinomas (classified as Tis or T1a,b)
- DOI 10.1002/(SICI)1097-0142(19981215)83:12<2516::AID-CNCR16>3.0. CO;2-#
- Schmidt F, Hartwagner KA, Spork EB, et al: Medical audit after 26,711 breast imaging studies: Improved rate of detection of small breast carcinomas (classified as Tis or T1a,b). Cancer 83:2516-2520, 1998 (Pubitemid 29019571)
- (1998) Cancer , vol.83 , Issue.12 , pp. 2516-2520
- Schmidt, F.¹ Hartwagner, K.A.² Spork, E.B.³ Groell, R.⁴

2
- 73349119689
- High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller
- Gonzalez-Angulo AM, Litton JK, Broglio KR, et al: High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 27:5700-5706, 2009
- (2009) J Clin Oncol , vol.27 , pp. 5700-5706
- Gonzalez-Angulo, A.M.¹ Litton, J.K.² Broglio, K.R.³

3
- 73349142700
- Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer
- Curigliano G, Viale G, Bagnardi V, et al: Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 27:5693-5699, 2009
- (2009) J Clin Oncol , vol.27 , pp. 5693-5699
- Curigliano, G.¹ Viale, G.² Bagnardi, V.³

4
- 73349122916
- Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy
- Burstein HJ, Winer EP: Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy. J Clin Oncol 27:5671-5673, 2009
- (2009) J Clin Oncol , vol.27 , pp. 5671-5673
- Burstein, H.J.¹ Winer, E.P.²

5
- 33344478381
- Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer
- DOI 10.1056/NEJMoa053028
- Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809-820, 2006 (Pubitemid 43290919)
- (2006) New England Journal of Medicine , vol.354 , Issue.8 , pp. 809-820
- Joensuu, H.¹ Kellokumpu-Lehtinen, P.-L.² Bono, P.³ Alanko, T.⁴ Kataja, V.⁵ Asola, R.⁶ Utriainen, T.⁷ Kokko, R.⁸ Hemminki, A.⁹ Tarkkanen, M.¹⁰ Turpeenniemi-Hujanen, T.¹¹ Jyrkkio, S.¹² Flander, M.¹³ Helle, L.¹⁴ Ingalsuo, S.¹⁵ Johansson, K.¹⁶ Jaaskelainen, A.-S.¹⁷ Pajunen, M.¹⁸ Rauhala, M.¹⁹ Kaleva-Kerola, J.²⁰ more..

6
- 26844503270
- Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
- DOI 10.1056/NEJMoa052306
- Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005 (Pubitemid 41464705)
- (2005) New England Journal of Medicine , vol.353 , Issue.16 , pp. 1659-1672
- Piccart-Gebhart, M.J.¹ Procter, M.² Leyland-Jones, B.³ Goldhirsch, A.⁴ Untch, M.⁵ Smith, I.⁶ Gianni, L.⁷ Baselga, J.⁸ Bell, R.⁹ Jackisch, C.¹⁰ Cameron, D.¹¹ Dowsett, M.¹² Barrios, C.H.¹³ Steger, G.¹⁴ Huang, C.-S.¹⁵ Andersson, M.¹⁶ Inbar, M.¹⁷ Lichinitser, M.¹⁸ Lang, I.¹⁹ Nitz, U.²⁰ more..

7
- 26844536978
- Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
- DOI 10.1056/NEJMoa052122
- Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005 (Pubitemid 41464706)
- (2005) New England Journal of Medicine , vol.353 , Issue.16 , pp. 1673-1684
- Romond, E.H.¹ Perez, E.A.² Bryant, J.³ Suman, V.J.⁴ Geyer Jr., C.E.⁵ Davidson, N.E.⁶ Tan-Chiu, E.⁷ Martino, S.⁸ Paik, S.⁹ Kaufman, P.A.¹⁰ Swain, S.M.¹¹ Pisansky, T.M.¹² Fehrenbacher, L.¹³ Kutteh, L.A.¹⁴ Vogel, V.G.¹⁵ Visscher, D.W.¹⁶ Yothers, G.¹⁷ Jenkins, R.B.¹⁸ Brown, A.M.¹⁹ Dakhil, S.R.²⁰ more..

8
- 33947317453
- BCIRG 006: Second interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in Her2neu positive early breast cancer patients
- abstr 52
- Slamon D, Eiermann W, Robert N, et al: BCIRG 006: Second interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in Her2neu positive early breast cancer patients. Breast Cancer Res Treat 100:S1, 2006 (abstr 52)
- (2006) Breast Cancer Res Treat , vol.100
- Slamon, D.¹ Eiermann, W.² Robert, N.³

9
- 33845914783
- 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial
- DOI 10.1016/S0140-6736(07)60028-2, PII S0140673607600282
- Smith I, Procter M, Gelber RD, et al: 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 369:29-36, 2007 (Pubitemid 46039831)
- (2007) Lancet , vol.369 , Issue.9555 , pp. 29-36
- Smith, I.¹ Procter, M.² Gelber, R.D.³ Guillaume, S.⁴ Feyereislova, A.⁵ Dowsett, M.⁶ Goldhirsch, A.⁷ Untch, M.⁸ Mariani, G.⁹ Baselga, J.¹⁰ Kaufmann, M.¹¹ Cameron, D.¹² Bell, R.¹³ Bergh, J.¹⁴ Coleman, R.¹⁵ Wardley, A.¹⁶ Harbeck, N.¹⁷ Lopez, R.I.¹⁸ Mallmann, P.¹⁹ Gelmon, K.²⁰ more..

10
- 74949141693
- Trastuzumab for patients with axillary-node-positive breast cancer: Results of the FNCLCC-PACS 04 trial
- Spielmann M, Roché H, Delozier T, et al: Trastuzumab for patients with axillary-node-positive breast cancer: Results of the FNCLCC-PACS 04 trial. J Clin Oncol 27:6129-6134, 2009
- (2009) J Clin Oncol , vol.27 , pp. 6129-6134
- Spielmann, M.¹ Roché, H.² Delozier, T.³

11
- 33847147313
- American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
- DOI 10.1200/JCO.2006.09.2775
- Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145, 2007 (Pubitemid 350003059)
- (2007) Journal of Clinical Oncology , vol.25 , Issue.1 , pp. 118-145
- Wolff, A.C.¹ Hammond, M.E.H.² Schwartz, J.N.³ Hagerty, K.L.⁴ Allred, D.C.⁵ Cote, R.J.⁶ Dowsett, M.⁷ Fitzgibbons, P.L.⁸ Hanna, W.M.⁹ Langer, A.¹⁰ McShane, L.M.¹¹ Paik, S.¹² Pegram, M.D.¹³ Perez, E.A.¹⁴ Press, M.F.¹⁵ Rhodes, A.¹⁶ Sturgeon, C.¹⁷ Taube, S.E.¹⁸ Tubbs, R.¹⁹ Vance, G.H.²⁰ more..

12
- 0026072872
- Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up
- Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 19:403-410, 1991
- (1991) Histopathology , vol.19 , pp. 403-410
- Elston, C.W.¹ Ellis, I.O.²

13
- 79951940612
- Benefits of trastuzumab-based therapy for women with small, node-negative, HER2-positive breast cancer
- Presented at the
- McArthur HL, Morris PG, Patil S, et al: Benefits of trastuzumab-based therapy for women with small, node-negative, HER2-positive breast cancer. Presented at the ASCO Breast Cancer Symposium, San Francisco, CA, October 8-10, 2009
- ASCO Breast Cancer Symposium, San Francisco, CA, October 8-10, 2009
- McArthur, H.L.¹ Morris, P.G.² Patil, S.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.